FDA grants fast-track review to 3 psychedelic drugs for hard-to-treat depression and other mental health conditions. The agency aims to speed development of novel therapies for patients with limited options.
The Food and Drug Administration announced it will offer expedited review to three psychedelic drugs being studied for treatment-resistant mental health conditions, including depression.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
Open map near US
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
U.S. asks Germany to help bring family of American Ebola patient from DRC
U.S. requests Germany's assistance to transport family members of an American Ebola patient from DRC.
American Ebola patient arrives in Berlin for treatment; WHO warns of further deaths.
An American Ebola patient has arrived in Berlin for treatment, sparking concern from the WHO over the outbreak.
US Treasury yields fall as US-Iran nuclear deal seen closer
US Treasury yields fall as US-Iran nuclear deal seen closer
Trump says US in 'final stages' of Iran talks, but outcome uncertain.
Donald Trump says the US is in 'final stages' of talks with Iran, but adds 'we'll see what happens'.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.